Temafloxacin, a new fluoroquinolone, is highly active in vitro against a broad spectrum of gram-positive and gramnegative aerobes and anaerobes, including those resistant to aminoglycosides and ,B-lactams (4, 12) . The pharmacokinetics of temafloxacin were investigated after single oral doses ranging from 100 to 1,000 mg (7) and were found to be essentially linear, with a low order of intersubject variability. The mean total body clearance and terminal disposition half-life were 223 ml/min and 7.7 h, respectively. Metabolism of temafloxacin was minimal, with glucuronidation and piperazine oxidation accounting for 3.5% and less than 2% of the dose, respectively. The major route of elimination was renal excretion of unchanged drug. The renal clearance (CLR) of unbound temafloxacin was slightly higher than the glomerular filtration rate (GFR), indicating that there was a contribution from tubular secretion. A small but statistically significant difference was found between the CLRs during the day (143 ml/min) versus at night (120 ml/min).
The study described herein was designed to evaluate the pharmacokinetics and safety of multiple oral doses of temafloxacin, thus allowing the formulation of appropriate dosing regimens for clinical use.
MATERIALS AND METHODS Subjects. The 36 male subjects who received temafloxacin in this study ranged in age from 19 to 28 years (mean, 22.4 years) and weighed between 56 and 102 kg (mean, 75 kg); their heights ranged from 168 to 199 cm (mean, 180 cm). All subjects were judged to be healthy on the basis of normal results of prestudy medical history, physical examination, ophthalmologic examination, neurologic assessment, 12-lead * Corresponding author.
electrocardiogram, electroencephalogram, urine drug and alcohol screens, and hematology (complete blood count and coagulation), serum chemistry, and urinalysis tests. None of the participants had a history of prior significant disease, history of allergy to fluoroquinolones, or history of current consumption of any medication on a chronic basis. The protocol was reviewed and approved by the ethical committee of Guy's Hospital. All subjects granted written, informed consent before entry into the study.
Drug administration. There were six groups of 10 subjects each in this trial. Each group received doses of 100, 200, 300, 400, 600, or 800 mg of temafloxacin every 12 h (ql2h) or placebo for 6.5 days. Subjects within each group were randomly assigned in a double-blind fashion to receive either temafloxacin (n = 6) or placebo (n = 4). The study proceeded from the 100-mg dose to successively higher doses as the safety of the preceding dose was established. Temafloxacin was supplied as the hydrochloride salt in 100-and 200-mg capsules (lots 05-023-VH and 05-024-VH, respectively; Abbott Laboratories, Abbott Park, Ill.), with 100-mg capsules being administered to the 100-and 300-mg-dose groups and 200-mg capsules being administered to the 200-, 400-, 600-, and 800-mg-dose groups. Subjects assigned to the placebo treatment received the corresponding number of matching placebo capsules. The morning dose was administered after an overnight fast of at least 8 h, and subjects did not eat breakfast until at least 2 h following dosing. Dinner was served at least 2 h before the evening dose, and the evening snack was served at least 2 (CLCRs) were determined the day prior to study dosing and the day following the last dose. Urinalysis, with examination for crystals and casts, was performed before dosing and then daily 2 to 4 h following the morning dose on study days 1 through 7. In addition, the subjects were questioned for any adverse events and were given diaries in which to record any unusual symptoms or adverse events for each dosing day. Sampling. Sampling was identical for the subjects receiving either temafloxacin or placebo. On study days 1 and 4, blood samples (5 ml) were collected via an indwelling venous catheter before the morning dose and 1, 2, 4, 8, and 12 h after dosing. On study days 2, 3, 5, and 6, blood samples were collected before the morning dose and 2 and 12 h after dosing. In addition, after the enrollment of the 100-and 200-mg-dose groups, the study protocol was amended to include blood sampling 2 h after the evening dose on study days 2 through 6. On study days 7 through 9, blood samples were collected before the morning dose and 1, 2, 4, 8, 12, 24, 36, 48, and 60 h following the dose. Plasma from the heparinized blood samples was separated by centrifugation and stored at -20°C until assayed.
Urine was collected before dosing and 0 to 6, 6 to 12, and 12 to 24 h after the morning dose of study days 1, 4, and 7. In addition, on days 7 to 9, urine was collected 24 10 ,ug/ml, with regression correlation coefficients averaging over 0.998.
Urine samples were diluted with mobile phase and supplemented with internal standard, followed by direct injection into the HPLC system by using the same system described for plasma. The calibration curves were linear from the quantitation limit of 1 statistical significance by likelihood ratio tests using objective function differences of the full and reduced models. The parameter estimates from the two programs were comparable, even though the latter took into account within-subject correlation.
An integrated model for the CLR of temafloxacin was constructed on the premise that the net CLR is the sum of three processes-glomerular filtration of unbound drug, tubular secretion, and tubular reabsorption. It was assumed that the renal clearance due to filtration (CLR filt) isfu * GFR. The free fraction (fu) is known from ultrafiltration experi- It is recognized that GFR and QR are correlated and that the latter will rarely be known in patients receiving temafloxacin, requiring some sort of simplifying assumption, such as GFR = 0. QR. Attempts to fit the interval clearance data with this assumption failed to reduce the objective function. In the case of temafloxacin, the erythrocyte/plasma concentration ratio is 1.0, and fu Tm'/Km' is <QR (-88 versus -1,200 ml/min); therefore, the equation can be collapsed, giving the following two equations: CLR,secr = fu * TmI(Km + Cp,avg) and CLR,secr+filt = fu [GFR + TmIl(Km + Cp,avg)], in which Tm is the maximal transport rate and Km is the concentration at which secretion is half maximal.
Although the latter equation is acceptable in the present population of individuals with normal renal function, the amount of tubular secretion would be reduced in renal impairment roughly in proportion to the number of functioning nephrons. This assumes the validity of the intact-nephron hypothesis, which requires that there is no differential decline in glomerular and tubular function. Using the approach that Tm in renal impairment = normal Tm (CLCR in renal impairment)/125 did not reduce the objective function in the present data set; however, in a more heterogeneous population than the present one, correction of the secretion segment of the equation for renal function will be necessary.
The relationship between the Qu and the interval CLR was chosen empirically. As tubular water reabsorption approaches 100%, one assumes that the same will occur with temafloxacin. Inspection of the experimental data indicated that fractional reabsorption of temafloxacin could be described by the expression 1 -e-( Qu), in which -y is a coefficient that describes temafloxacin's intrinsic characteristics for tubular reabsorption. It is acknowledged that other equations with a more gradual approach to the asymptote may also work and be more appropriate, but the current data set had no information about Q1, of <0.5 or >4 ml/min. It (20) , using procedures GLM, MEANS, and STEPWISE. Regression was used to evaluate the linearity of parameters which should increase proportionally with dose (Cmin, Cmax, AUC, and Ae). High coefficients of determination (R2 >0.9) were assumed to be indicative of linearity. These kinetic parameters were also dose normalized (in terms of 100-mg dose) to allow intergroup analysis of variance (ANOVA), simple regression, and multiple linear regression. Circadian phenomena were evaluated by using a paired Student's t test to compare kinetic parameters from the morning and evening doses. Statistical significance was assumed at the 5% level.
RESULTS
Demographics and safety. The demographics of the study participants receiving temafloxacin are summarized in Table  1 . No statistically significant intergroup differences were found by ANOVAs of age, height, weight, body surface area (BSA), or CLCR. In general, the incidence of adverse events was higher in the placebo group than in the temafloxacin group. Sixteen of 36 (44.4%) temafloxacin subjects reported at least one adverse event, while 18 of 24 (75.0%) placebo subjects reported at least one adverse event. The difference was statistically significant (P < 0.05). The total numbers of adverse events for the temafloxacin and placebo subjects were 21 and 27, respectively. There was no dose-related trend in adverse events, which were generally mild, with headache being most frequently reported (22% of temafloxacin subjects and 46% of placebo subjects). No clinically significant changes were observed during any of the physical, ophthalmologic, electroencephalogram, or electrocardiogram examinations or in the results of laboratory tests. There were no statistically significant differences or clinically significant changes in CLCR for any dose group, and urinalyses detected no temafloxacin crystals.
Concentrations in plasma. The group mean concentration in plasma profiles for the 100-, 300-and 600-mg ql2h regimens are illustrated in Fig. 1 ; those for the 200-, 400-and 800-mg ql2h regimens are presented in Fig. 2 . The noncompartmental and model-dependent pharmacokinetic parameters of multiple-dose temafloxacin are summarized in Table   380 GRANNEMAN ET AL. which were computed from day 3 through day 7, were 1.02 ± 0.21, 0.60 ± 0.14, and 0.47 + 0.11 ,ug/ml/100 mg administered, respectively. The study-wide dose-normalized averages of the Cm. and AUCam, which were measured for the morning doses of days 4 and 7, were 1.16 ± 0.23 ,ug/ml/100 mg and 9.66 + 1.92 ,ug * h/ml/100 mg, respectively. The group mean AUCam values for the six dosage groups and the corresponding regression line, using reciprocal variance weights, are shown in Fig. 3 . ANOVAs for the dose- normalized parameters failed to show significant intergroup differences, except for the case of Cmin pm per dose (P = 0.037). Slower absorption rate constants were observed with increasing dose size, probably contributing to the slight increase in Cmin per dose with increasing dose size. The decrease in the absorption rate constants confirms earlier observations of solubility-limited dissolution with larger doses (7). Urinary excretion. The principal route of elimination of temafloxacin was by renal clearance of unchanged drug. Urinary drug concentrations were typically around 100 times higher than the corresponding concentrations in plasma. Two days after the last dose, the group mean drug concentrations were still above the MIC for 90% of strains tested for most urinary pathogens, ranging from 3 ,ug/ml after 100 mg ql2h to 27 ,ug/ml after 800 mg ql2h. The 4 Q X 'e 'e temafloxacin for days 4 and 7 were 70% + 12%, 74% + 18%, 65% ± 11%, 63% ± 9%, 72% + 11%, and 55% ± 4% of the respective 100-, 200-, 300-, 400-, 600-, and 800-mg ql2h doses. Although there was a trend for recoveries to diminish slightly with increasing dose size, the intergroup differences were not statistically significant by ANOVA (P = 0.09). The group mean CLRs ranged from 147 ± 26 ml/min for the 200-mg ql2h group to 94 ± 14 ml/min for the 800-mg ql2h group and averaged 119 + 32 ml/min study wide. There was a trend of declining CLR with increasing dose size, and the intergroup differences approached statistical significance when assessed by ANOVA (P = 0.065).
TEMAFLOXACIN PHARMACOKINETICS AFTER MULTIPLE
Circadian effects. The study-wide ratio of Cminam to Cminjpm was 1.27 ± 0.13, and the intrasubject difference in the minima was highly significant (P < 0.001). This phenomenon, which was recognized during the analyses of the samples from the 100-and 200-mg ql2h regimens, could either be due to slower clearance of temafloxacin during the nighttime interval or to delayed and protracted absorption of the evening doses. To further investigate the effect, the protocol was amended to allow collection of samples 2 h after the evening doses. Analyses of these additional samples showed that absorption of the evening doses was indeed delayed. In general, the concentrations of temafloxacin 2 h after the evening doses were only slightly elevated over those observed immediately prior dosing ( Fig. 1 and 2 ). Circadian effects were also noted in the urinary excretion rates: greater recoveries were noted in the daytime collection intervals relative to the nighttime intervals, and there were distinctive sinusoidal patterns in the elimination phase after the day 7 dose, with lower-than-expected excretion rates in the evening intervals (Table 3) . For example, the study-wide mean morning (0 to 12 h) and evening (12 to 24 h) CLRs calculated after the day 7 dose were 145 ± 62 and 111 ± 36 ml/min; the intrasubject differences were highly significant by paired t test (P < 0.001). Significant differences (P < 0.001) were also noted in the Q"s in the day (1.80 ± 0.58 ml/min) and night (1.00 ± 0.43 ml/min) intervals of day 7, as well as study wide (1.61 ± 0.43 versus 1.08 ± 0.33 ml/min; P < 0.001).
Model-dependent pharmacokinetic parameters. To better understand the kinetics of temafloxacin in the present study, the plasma drug concentration-versus-time data were fitted with a variety of models. Although the overall curve shapes could be coarsely described by a one-compartment model, fine structure of the curves, such as the differences in the morning and evening minima, could not be reproduced, even when the model allowed for different absorption lag times and rate constants for the morning and evening doses. However, if the model allowed for a longer lag time in absorption and slower clearance in the night interval, the observed differences in Cmin could be simulated. The results of the regressions of group mean data using this model are reproduced in Fig. 1 and 2 .
The group mean overall elimination rate constants estimated from the regressions ranged from 0.094 + 0.006 h-1 for the 200-mg dose ql2h group to 0.070 ± 0.007 h-1 for the 800-mg dose ql2h group, with corresponding group harmonic mean half-lives ranging from 7.4 to 9.9 h and averaging 8.4 h study wide. Even though there was only a 13% CV in the terminal-phase rate constant study wide, the intergroup differences were found to be statistically significant by ANOVA (P = 0.0006). In contrast, no intergroup differences were found in the following: (i) CLT/F, which ranged from 171 to 220 ml/min and averaged 197 ml/min study-wide, (ii) CLNR/F, which ranged from 64 to 96 ml/min and averaged ml/min, or (iii) V./F, which ranged from 139 to 152 liters and averaged 143 liters. The day/night clearance ratio was statistically significantly greater than unity, averaging 1.31 study wide; no intergroup differences in the ratio were detected by ANOVA.
Intrasubject and intersubject variability. The intrasubject variability in the steady-state kinetics of temafloxacin, which was assessed by computing CVs for Cmin,am and Cmin,pm for day 3 through day 7, was quite low for an orally administered drug, averaging under 10% study wide. The intersubject variability in CLT/F was also quite low, with a study-wide CV of only 20%. The sources of this variability were evaluated by multiple linear regression, using age, tobacco use, BSA, CLCR, average Q, (milliliters per minute), and Cp,avg as regressors. BSA (P = 0.018), Qu (P = 0.001), and Cp,avg (P < 0.001) were found to be statistically significant, and the regression accounted for 61% of the intersubject variability in CLT/F. Similarly, BSA (P = 0.024), Q, (P = 0.042), and Cp,avg (P < 0.001) were found to be statistically significant regressors for CLR, explaining 54% of the intersubject variability. Substitution of body weight or lean body mass for BSA gave similar results, with BSA or lean body mass explaining a slightly larger proportion of the variance than total weight. Although the multiple linear regression equations for CLT/F and CLR demonstrated the importance of milligram-per-BSA (or milligram-per-kilogram) dosage, Q, and Cp,avg in the intersubject variability of temafloxacin, the equations lacked physiologic context. This deficiency was addressed by assuming that temafloxacin's CLR has three components: filtration, secretion, and reabsorption. The following semiempirical equation was elaborated to explore the relationship between the interval CLRs with CLCR, Cp,avg, and Qu as covariates: CLR = fg [ The observed relationship between Qu and CLR is plotted in Fig. 5 .
DISCUSSION
In this first report of the safety and pharmacokinetics of temafloxacin after multiple oral doses, it was found that this antibacterial agent was well tolerated at dosages as high as 800 mg ql2h for 6.5 days. The 400-, 600-, and 800-mg ql2h regimens produced C,mis that averaged above 2 ,ug/ml, which is above the MIC90 for the majority of the organisms examined by Hardy et al. (12) . Urinary temafloxacin concentrations were many multiples of MIC90 for urinary tract pathogens tested, even for the 100-mg ql2h regimen, which produced concentrations ranging from 50 to 157 ,ug/ml at steady state and averaging 6.5 ,g/ml in the 36-to 48-h collection interval after the last dose.
As a first approximation, the kinetics of temafloxacin may be considered to be linear, since Cmin and Cma, were highly correlated with dose size, respectively averaging slightly above 0.5 and 1 ,ug/ml/100 mg administered as a ql2h regimen. Similarly, no significant interdose differences in CLT/F, VP/F, and CLNR/F were found by ANOVA. However, there were several pharmacokinetically interesting observations in this study which were deviations from perfect linearity and which appear to be class phenomena among the quinolone antibacterial agents. First, there were apparent circadian effects in the rates of absorption and elimination of temafloxacin, with both declining in the evening intervals. Second, the study-wide CLT/F of 197 ml/min from this multidosing study was lower than the 223-ml/min value reported after single doses ranging from 100 to 1,000 mg (7). The 8.4-h mean half-life in the present study also exceeded the 7.7-h estimate from the single-dose study. Differences between single-and multiple-dose clearances and between morning and evening dose minima are also present for ciprofloxacin, enoxacin, pefloxacin, and ofloxacin. In three separate multiple-dosing studies with ciprofloxacin (2, 15, 16) , the apparent steady-state clearances were around 24% lower than single-dose clearances and minima preceding the morning doses were uniformly lower than those preceding the evening doses. Similar observations were made with enoxacin: morning minima were higher, and total clearance was reduced 21 to 49% upon multiple dosing (27) . Plots of ofloxacin twice-a-day multipledosing curves also show higher minima preceding the morning doses (13) . With pefloxacin, administered twice a day both orally and intravenously, the steady-state clearances were 28 to 30% lower than those following the initial dose (6) .
There is substantial evidence that the rate of absorption of drugs and nutrients is generally lower in the evening (10, 17, 24) . For the present study with temafloxacin, absorption was delayed after the evening dose, and part of the circadian effect with Cmin was partially attributable to this effect. In the absence of other effects, the 2-h difference in the lag times for evening and morning doses should produce about a 10 to 15% intraday difference in Cmin at steady state.
Formulations of temafloxacin developed subsequent to this study have been evaluated with and without food, with the finding that rate of absorption is not affected and that the extent of absorption is actually slightly enhanced by food (9) . With these formulations, differences in Cmin for the morning and evening doses have been much less pronounced than those of the present study.
The urinary recovery data and the kinetic modeling of plasma temafloxacin profiles indicated that part of the circadian effect was related to slower clearance in the night interval. Since renal clearance is the predominant pathway for temafloxacin's elimination, it was examined in some detail, with the finding that in addition to the linear process of glomerular filtration of unbound drug, there appears to be a contribution from a concentration-dependent process. This finding, which is almost certainly due to tubular transport, was modelled with the standard hyperbolic function (26) , with resulting estimates of 197 ,ug/min for the maximal secretion rate and 1.57 ,ug/ml for the concentration at which the rate is half maximal. The partial saturation of tubular secretion within the investigated dosage range thus appears to be the major reason for the trend of decreasing CLR, CLT/F, and 3 values with increasing dose sizes. As the steady-state concentrations of temafloxacin in plasma exceeded the half-maximal rate for transport, CLR declined, producing comparable effects on CLT/F and P. The 200-mg ql2h regimen produced a mean concentration of 1.4 Ii',/ml, which is comparable to the estimated Km (1.6 jig/ml). For this reason, the effect was most pronounced at the low dose levels. The Vm and Km estimates, which are predicated on the assumption that there is no reabsorption of temafloxacin under high urine flow conditions (>4 ml/min), predict that secretion accounts for 18 and 12% of CLT/F, respectively, for the regimens of 300 to 600 mg ql2h that were utilized in phase II and III trials.
The renal secretion effects for temafloxacin are certainly not unique among the quinolones. Tubular transport of enoxacin, norfloxacin, ciprofloxacin, and ofloxacin has also been inferred by high CLR/CLCR ratios or has been confirmed by demonstration of significant reductions in CLR when coadministered with probenecid, an inhibitor of anionic tubular transport (5, 18, 23, 25, 28, 29) . Even fleroxacin, which has a CLR/CLCR ratio below unity, appears to have probenecid-sensitive tubular secretion (22) . Although the polar quinolones such as ciprofloxacin and norfloxacin do not show distinctive dose dependence in CLR, trends of declining CLR with increasing dose size are apparent for the more nonpolar agents, ofloxacin (18) and fleroxacin (27) . Recognition of the concentration dependence of secretion also largely explains the reductions in the terminal-phase rate constant and CLT/F of temafloxacin in going from single to multiple dosing; similar effects may partially account for single-dose versus steady-state kinetic differences reported for other quinolones.
Theoretically, renal tubular reabsorption is possible for most drugs which are capable of transversing cellular barriers. The shape of the curve of reabsorption rate versus Q,, varies among compounds and is dependent on a host of factors such as molecular size, lipophilicity, and degree of ionization (14) . For example, the CLR of ethanol is directly proportional to flow, whereas larger and less permeable compounds show their greatest flow dependence under very low flow conditions. The results of the nonlinear regression of the temafloxacin CLR data indicate that temafloxacin is in the latter class and that the greatest reabsorption occurs when Q,, is below 1 ml/min. Above this rate there was little flow dependence in CLR. The reabsorption effect is potentially of some clinical relevance, since it predicts that higher AUCs would be observed in oliguric patients and that AUC would decrease as normal urine flow was reestablished. On the other hand, concomitant diuretic use with temafloxacin would be expected to have minimal kinetic effects through alteration of urine flow; however, diuretic effects of enhanced GFR or inhibition of secretion are possible.
Reduction in renal function at night has been widely studied and reviewed, with the finding that the primary synchronizer of circadian rhythms appears to be the daily schedule of activity and sleep (3, 11) . Cardiac output, QR GFR, and the hormones regulating renal function have parallel circadian rhythms, with maxima occurring during the activity periods. The CLR model described above does VOL. 36, 1992 not address the theoretical QR dependence in secretion-this is not a great concern in the present study, since normal QR is >> T,,I/kp-nor does it account for circadian effects in GFR or QR and their possible confounding effects on QU and the extent of reabsorption. Evaluation of the study data suggests that the day-versus-night differences in Cmin were largely due to slower and delayed absorption of the evening dose and to reduction in the CLR at night as a result of reduced urine flow; however, circadian effects in GFR and QR cannot be totally ruled out, since neither was evaluated in the present study.
It is difficult to attach any clinical significance to the circadian effects in the pharmacokinetics of temafloxacin or of other fluoroquinolones. Similarly, the minor departure from linearity observed with the CLR of temafloxacin at low concentrations has little clinical relevance, particularly when considered in light of the favorable safety profile from the present study. Overall, the study-wide intersubject variability in CLT/F was only 20% (18% when normalized by BSA), which is quite low for an orally administered drug, considering the eightfold range in dosage and the 21% CV in CLCR. Since intrasubject between-day variability in Cmins was under 10%, it is also inferred that the extent of absorption of temafloxacin in the present study was quite consistent within subjects. Overall, it thus appears that the pharmacokinetics of temafloxacin are essentially linear, reproducible within a subject, and predictable among subjects.
